The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Early prevention of myeloma: dara for high-risk MGUS and low-risk SMM
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the first report of the efficacy and safety of the single-arm, phase II trial of daratumumab monotherapy in patients with low-risk smoldering multiple myeloma. Early therapeutic intervention in this precursor patient population appears promising and required long-term follow-up. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
